Expanding the Use of PARP Inhibitors in Breast Cancer

H&O  Which patients with breast cancer are currently eligible for poly(ADP-ribose) polymerase (PARP) inhibition? TT  For this question, I refer to the National Comprehensive Cancer Network […]

PARP Inhibitors in Prostate Cancer: Practical Guidance for Busy Clinicians

  Abstract: The management of prostate cancer entered a new era of biomarker-driven therapy in May of 2020, when the US Food and Drug Administration (FDA) […]

Update on Drugs in Advanced Ovarian Cancer 

  H&O  What is the prognosis for patients with ovarian cancer, and how has it changed in recent years? DO  Ovarian cancer is usually diagnosed at […]

Management of Newly Diagnosed or Recurrent Ovarian Cancer

  Abstract: The treatment of newly diagnosed or recurrent ovarian cancer has changed significantly in recent years, with an increased number of treatment options available. Surgery […]